CoLucid Pharmaceuticals Inc. (CLCD) Shares Down 1.6%
CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) shares dropped 1.6% during mid-day trading on Thursday . The stock traded as low as $8.39 and last traded at $8.55, with a volume of 77,758 shares. The stock had previously closed at $8.69.
Separately, Zacks Investment Research raised shares of CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 17th.
The firm’s market capitalization is $131.11 million. The stock has a 50-day moving average of $8.86 and a 200 day moving average of $7.01.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last announced its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.22. Equities analysts forecast that CoLucid Pharmaceuticals Inc. will post ($4.01) EPS for the current year.
In other CoLucid Pharmaceuticals news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $8.45, for a total value of $1,293,086.60. The sale was disclosed in a filing with the SEC, which is available through this link.
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.